T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
In this free webinar, gain insight into the principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development. Attendees will learn how mRNA synthesis, LNP ...
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market ...
WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...
Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief ...
Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...
Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...
The Global Peripheral T-Cell Lymphoma Market is poised for significant growth, driven by a rising incidence of lymphoma and adoption of novel targeted therapies and immunotherapies. Peripheral T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results